InspireMD, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45779A8466
USD
1.92
-0.01 (-0.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About InspireMD, Inc. stock-summary
stock-summary
InspireMD, Inc.
Pharmaceuticals & Biotechnology
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Company Coordinates stock-summary
Company Details
4 Menorat Hamaor St. , TEL AVIV-YAFO MA : 6744832
stock-summary
Tel: 1 857 45365531 888 7766804
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.12%)

Foreign Institutions

Held by 6 Foreign Institutions (16.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Paul Stuka
Chairman of the Board
Mr. Marvin Slosman
Chief Executive Officer, Director
Mr. Isaac Blech
Independent Vice Chairman of the Board
Mr. Thomas Kester
Director
Dr. Gary Roubin
Director
Mr. Michael Berman
Independent Director
Dr. Campbell Rogers
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 100 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

-204.42%

stock-summary
Price to Book

4.95